Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.

Feldmann, Georg

Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. [electronic resource] - Cancer biology & therapy Oct 2011 - 598-609 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1555-8576

10.4161/cbt.12.7.16475 doi


Animals
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Bridged Bicyclo Compounds, Heterocyclic--administration & dosage
Cell Line, Tumor
Cell Movement--drug effects
Cell Proliferation--drug effects
Cyclic N-Oxides
Cyclin-Dependent Kinases--antagonists & inhibitors
Deoxycytidine--administration & dosage
Drug Resistance, Neoplasm--genetics
Enzyme Inhibitors--pharmacology
Humans
Indolizines
Male
Mice
Mice, Nude
Pancreatic Neoplasms--drug therapy
Phosphorylation--drug effects
Pyridinium Compounds--administration & dosage
Receptors, Notch--genetics
Retinoblastoma Protein--metabolism
Signal Transduction
Transforming Growth Factor beta--metabolism
Xenograft Model Antitumor Assays
ral GTP-Binding Proteins--metabolism
Gemcitabine